@aquariusgirl you are taking mitosynergy currently?
Check this out: I think proper copper & biotin have helped my mitos
http://m.jn.nutrition.org/content/137/1/25.full
This is a 2006 article from Bruce Ames & co which I thought was interesting.
Apart from the importance of biotin to mito function & in a further step heme synthesis, there is a really interesting throwaway line about how copper & biotin work together :
However, as expected from copper's role in complex IV, the recovery of complex IV was more efficient when copper and biotin were both added to the medium (data not shown).
@whodathunkit , we had been talking about B2 for a while when someone whose user name started out ppodhjaski (something like that) was here and brought up about FMN and thioredoxin. Yes, B2 is important.
I have a feeling that all the good news regarding coffee and disease might be from its high riboflavin content.
http://nutritiondata.self.com/foods-000109000000000000000.html
35mg in a cup of decaf!
Something seems wrong with that measurement of riboflavin in coffee. This site says .2mg per 8 ounce cup.
Oh shoot, sorry. That initial reading was for a 200 calorie serving! And coffee has about zero calories.
Good eye!
Patients with chronic liver disease have a tendency to accumulate an excessive amount of iron in their liver parenchyma. Those with alcoholic liver disease, nonalcoholic steatohepatitis or hepatitis C virus infection have a particular tendency toward secondary hemosiderosis.
Patients who have secondary iron overload must be distinguished from those with hereditary hemochromatosis, in which a primary genetic defect leads to an excessive hepatic and total-body iron load. The level of iron loading is much greater in patients with primary hemochromatosis than in those with secondary hemosiderosis.
As many as 30 percent of patients with liver disease have high serum iron levels, and 10 percent have excessive amounts of iron in their liver tissue.30,31 The reason for the iron excess is not known, but postulated mechanisms include the release of iron from injured hepatocytes and their uptake by Kupffer cells, acute-phase reactions associated with chronic inflammatory states, increased uptake of iron through the gastrointestinal tract, and ineffective erythropoiesis with redistribution of iron from sites of utilization to sites of storage. The most likely mechanisms of liver injury from excess iron are increased generation of free radicals and increased peroxidation of lipids, which, in turn, lead to mitochondrial dysfunction, lysosomal fragility and cell death.
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
Kowdley KV1, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network.
Author information
Abstract
Serum ferritin (SF) levels are commonly elevated in patients with nonalcoholic fatty liver disease (NAFLD) because of systemic inflammation, increased iron stores, or both. The aim of this study was to examine the relationship between elevated SF and NAFLD severity. Demographic, clinical, histologic, laboratory, and anthropometric data were analyzed in 628 adult patients with NAFLD (age, ≥ 18 years) with biopsy-proven NAFLD and an SF measurement within 6 months of their liver biopsy. A threshold SF >1.5 × upper limit of normal (ULN) (i.e., >300 ng/mL in women and >450 ng/mL in men) was significantly associated with male sex, elevated serum alanine aminotransferase, aspartate aminotransferase, iron, transferrin-iron saturation, iron stain grade, and decreased platelets (P < 0.01). Histologic features of NAFLD were more severe among patients with SF >1.5 × ULN, including steatosis, fibrosis, hepatocellular ballooning, and diagnosis of NASH (P < 0.026). On multiple regression analysis, SF >1.5 × ULN was independently associated with advanced hepatic fibrosis (odds ratio [OR], 1.66; 95% confidence interval [CI], 1.05-2.62; P = 0.028) and increased NAFLD Activity Score (NAS) (OR, 1.99; 95% CI, 1.06-3.75; P = 0.033).
CONCLUSIONS:
A SF >1.5 × ULN is associated with hepatic iron deposition, a diagnosis of NASH, and worsened histologic activity and is an independent predictor of advanced hepatic fibrosis among patients with NAFLD. Furthermore, elevated SF is independently associated with higher NAS, even among patients without hepatic iron deposition. We conclude that SF is useful to identify NAFLD patients at risk for NASH and advanced fibrosis.
For a long time, bile acids were considered solely as steroidal detergents and emulsifying agents. But now their roles as regulatory/signaling molecules have been recognized. They are ligands for the orphan nuclear receptors FXR and PXR. Through activating FXR, bile acids regulate many genes in the liver and intestine, which modulate the biosynthesis and metabolism of bile acids and lipoproteins and determine the composition of the intestinal flora and fuana [3, 7, 8, 17, 18]. Recently, δ-aminolevulinate synthase, the rate limiting enzyme of porphyrin-heme synthesis, has also been identified as a gene regulated by FXR, indicating a role of bile acids and their precursors in regulating hepatic heme biosynthesis [19]. The secondary bile acid, lithocholic acid activates PXR [20] and the vitamin D receptor [21, 22]. PXR in turn regulates the expression of CYP3A4, which encodes the major drug and xenobiotic catabolizing P450 isozyme in human liver. The secondary bile acid, ursodeoxycholic acid activates the glucocorticoid receptor and exerts immunomodulatory effects [23–25]. Bile acids also activate several signaling pathways including the c-Jun NH2- terminal kinase (JNK) 1/2 pathway (to feedback inhibit bile acid biosynthesis) [8], the protein kinase B (AKT) pathway (to regulate glucose metabolism) [8, 26], FXR, short heterodimer partner (SHP), liver X receptor (LXR), and the sterol regulatory element- binding protein (SREBP)-1c pathway (to regulate lipid metabolism) [8, 27], the extracellular-signal-regulated kinases (ERK) pathway (to prevent apoptosis) [28, 29], and the epidermal growth factor receptor (to modulate intestinal permeability) [30]. A recently identified G protein-coupled bile acid receptor (TGR5) [31] further expands the function of bile acids and their roles in energy metabolism [32], inflammation [33, 34], and gallbladder contractility [35]. Bile acids also affect cardiac function by regulating vascular tone and myocardial contractility, but the underlying mechanism for this remains largely unknown [36].
29 rs3808607 CYP7A1 G/T T G 0.4758 58500364 G TT OK
30 rs3824260 CYP7A1 A/G G A 0.4493 58500630 A GG OK
31 rs3732860 CYP8B1 C/T C T 0.3157 42872519 T TT HOMOZYGOUS
32 rs35724 NR1H4 C/G C G 0.3996 100561599 G CG HETEROZYGOUS
33 rs10808739 CYP7B1 A/G G A 0.2175 64727702 A AA HOMOZYGOUS
34 rs72554620 CYP7B1 C,T C T NA 64604752 A GG OK
35 rs7083869 AKR1C4 A/G G A 0.2045 5202331 A GG OK
36 rs3731859 GPBAR1 A/G G A 0.4489 218259498 A AG HETEROZYGOUS
154 rs9938550 HSD3B7 A/G A G 0.4934 30987820 G GG HOMOZYGOUS
RESULTS:
Mutations in the SRD5B1 gene were identified in all three children. Patient MS was homozygous for a missense mutation (662 C>T) causing a Pro198Leu amino acid substitution; patient BH was homozygous for a single base deletion (511 delT) causing a frame shift and a premature stop codon in exon 5; and patient RM was homozygous for a missense mutation (385 C>T) causing a Leu106Phe amino acid substitution.
All had liver biopsies showing a giant cell hepatitis; in two, prominent extramedullary haemopoiesis was noted. MS was cured by treatment with chenodeoxycholic acid and cholic acid; BH showed initial improvement but then deteriorated and required liver transplantation; RM had advanced liver disease when treatment was started and also progressed to liver failure.